Antibodies

14 November 2016

Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis

14 November 2016

Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers

14 November 2016

Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma

14 November 2016

Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck

14 November 2016

Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Efficacy and Safety in Previously Treated Patients With Advanced Form of Bladder Cancer

14 November 2016

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer

14 November 2016

Leap Therapeutics Presents Data from Phase 1 Study of GITR Agonist

14 November 2016

Phase III GiACTA Study Shows Genentech’s Actemra® is Superior to Steroids Alone in Maintaining Steroid-Free Remission for People with Giant Cell Arteritis

14 November 2016

Celltrion Healthcare Showcases Data Supporting Efficacy and Safety of Both CT-P10 and CT-P13 Biosimilars

11 November 2016

Corvus Pharmaceuticals Announces Preliminary Phase 1/1b Clinical Data with Lead Checkpoint Inhibitor CPI-444 Demonstrating Safety and Evidence of Anti-Tumor Activity as a Single Agent in Patients with Advanced Refractory Cancers

11 November 2016

Xencor Presents Preclinical Data on XmAb20717 Dual Checkpoint Blockade and Additional Bispecific Antibody Candidates at Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

11 November 2016

BeiGene Presents Updated Clinical Data on PD-1 Antibody BGB-A317 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 31st Annual Meeting

11 November 2016

Compugen Immune Checkpoint Program Demonstrates Potential for Development of New Cancer Immunotherapy Treatments

11 November 2016

European Commission Approves STELARA® (ustekinumab) for Treatment of Adults with Moderately to Severely Active Crohn’s Disease

11 November 2016

Atreca Presents Promising Findings from Lead Antibody Program at Society for Immunotherapy of Cancer (SITC) Annual Meeting

11 November 2016

Bristol-Myers Squibb’s Opdivo® (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer

10 November 2016

Anthera Announces that the Blisibimod CHABLIS-SC1 Phase 3 Study Did Not Achieve the Primary Endpoint in Patients with Active Systemic Lupus Erythematosus

10 November 2016

Theratechnologies Announces Results from the Last Pivotal Phase III Trial of HIV Long Acting Biologic (LAB) Investigational Antiretroviral Ibalizumab.

10 November 2016

Single Dose of Omeros’ Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade of the Alternative Pathway

10 November 2016

Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides and Primary Cutaneous Anaplastic Large Cell Lymphoma

10 November 2016

Opdivo (nivolumab) Demonstrates Overall Survival Benefit in Patients With Unresectable Advanced or Recurrent Gastric Cancer in Phase 3 Study

10 November 2016

Immunocore Presents Positive Monotherapy Data in Uveal Melanoma at the Society for Melanoma Research (SMR) 2016 Congress

10 November 2016

Prothena Reports Results from Phase 1b Study of PRX002 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease

8 November 2016

Imago BioSciences Enrolls First Patient in Phase 1/2 Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome

8 November 2016

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

8 November 2016

Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma

8 November 2016

Surface Oncology Announces First Fully Human CD47 Antibody Entering Clinical Development in 2017

8 November 2016

Preliminary phase 1/2 efficacy data of lirilumab in combination with Opdivo (nivolumab) in patients with advanced platinum refractory squamous cell carcinoma of the head and neck to be presented during SITC meeting

8 November 2016

New XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual Meeting

8 November 2016

BioInvent reports clinical hold on BI-505 phase II study

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Report Package: Claudin 18.2-Targeted Immunotherapeutics

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins